Intravenous liposomal HCQ or free HCQ given intraperitoneally (IP) was assessed in combination with the autophagy-inducing EGFR inhibitor gefitinib in immunocompromised mice bearing established gefitinib-resistant JIMT-1 breast cancer xenografts. Here, EGFR is linked to breast carcinoma.